OncoMatch/Clinical Trials/NCT05874401

Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan

Is NCT05874401 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Trilaciclib and Topotecan for extensive-stage small-cell lung cancer.

Phase 4RecruitingPharmacosmos A/SNCT05874401Data as of May 2026

Treatment: Trilaciclib · Topotecan — This is a multicenter, randomized, double-blind, placebo-controlled study to assess whether trilaciclib administered prior to topotecan is non-inferior to placebo administered prior to topotecan with regard to overall survival.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Disease stage

Required: Stage IV

ES-SCLC

Prior therapy

Max 2 prior lines

Min 1 prior line

Must have received: platinum-based chemotherapy — first-line

First-line regimen must have been a platinum-containing combination

Cannot have received: topoisomerase I inhibitor (topotecan, trilaciclib)

History of topotecan (or other topoisomerase I inhibitor) or trilaciclib treatment for SCLC

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify